天津科技大学学报

参考文献

[1]Shang Y,Baumricker C R,Green M H.c-Myc is a major mediator of the synergistic growth inhibitory effects of retinoic acid and interferon in breast cancer cells[J].Journal of Biological Chemistry,1998,273(46):30608-30613.

[2]Kusnierczyk H,Pajtasz-Piasecka E,Koten J W,et al.Further development of local IL-2 therapy of cancer:Multiple versus single IL-2 treatment of transplanted murine colon carcinoma[J].Cancer Immunology Immunotherapy,2004,53(5):445-452.

[3]Crockford D,Turiman N,Allan C,et al.Thymosin beta4:Structure,function,and biological properties supporting current and future clinical applications[J].Annals of the New York Academy of Sciences,2010,1194(4):179-189.

[4]曹瑞珍,薛燕,李大力.抗肿瘤多糖研究进展[J].内蒙古民族大学学报:自然汉文版,2004,19(6):657-658.

[5]Lohmueller J,Finn O J.Current modalities in cancer immunotherapy:Immunomodulatory antibodies,CARs and vaccines[J].Pharmacology&Therapeutics,2017,178:31-47.

[6]Hassel J C,Heinzerling L,Aberle J,et al.Combined immune checkpoint blockade(anti-PD-1/anti-CTLA-4):Evaluation and management of adverse drug reactions[J].Cancer Treatment Reviews,2017,57:36-49.

[7]Wang Q,Wu X.Blocking the PD-1/PD-L1 pathway in glioma:A potential new treatment strategy[J].Journal of Hematology&Oncology,2017,10(1):81.

[8]Gross G,Waks T,Eshhar Z.Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J].Proceedings of the National Academy of Sciences of the United States of America,1989,86(24):10024-10028.

[9]Pofler D L,Levine B L,Kalos M,et a1.Chimeric antigen receptor modified T cells in chronic lymphoid leukemia[J].New England Journal of Medicine,2011,365(8):725-733.

[10]Savoldo B,Ramos C A,Liu E,et al.CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients[J].Journal of Clinical Investigation,2011,121(5):1822-1826.

[11]Jensen M C,Riddell S R.Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells[J].Immunological Reviews,2014,257(1):127-144.

[12]Ramos C A,Dotti G.Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy[J].Expert Opinion on Biological Therapy,2011,11:855-887.

[13]Kershaw M H,Westwood J A,Parker L L,et a1.A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer[J].Clinical Cancer Research,2006,12(20):6106-6115.

[14]Maher J,Brentjens R J,Gunset G,et al.Human Tlymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor[J].Nature Biotechnology,2002,20(1):70-75.

[15]Milone M C,Fish J D,Carpenito C,et al.Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo[J].Molecular Therapy,2009,17(8):1453-1464.

[16]Kowolik C M,Topp M S,Gonzalez S,et al.CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells[J].Cancer Research,2006,66(22):10995-11004.

[17]Loskog A,Giandomenico V,Rossig C,et al.Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells[J].Leukemia,2006,20(10):1819-1828.

[18]Carpenito C,Milone M C,Hassan R,et al.Control of large,established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains[J].Proceedings of the National Academy of Sciences of the United States of America,2009,106(9):3360-3365.

[19]Cheadle E J,Gornall H,Baldan V,et al.CAR T cells:Driving the road from the laboratory to the clinic[J].Immunological Reviews,2014,257(1):91-106.

[20]Hu W S,Pathak V K.Design of retroviral vectors and helper cells for gene therapy[J].Pharmacological Reviews,2000,52(4):493-511.

[21]Montini E,Cesana D,Schmidt M,et al.Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration[J].Nature Biotechnology,2006,24(6):687-696.

[22]Till B G,Jensen M C,Wang J,et al.Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells[J].Blood,2008,112(6):2261-2271.

[23]Maiti S N,Huls H,Singh H,et al.Sleeping beauty system to redirect T cell specificity for human applications[J].Journal of Immunotherapy,2013,36(2):112-123.

[24]Cartellieri M,Koristka S,Arndt C,et al.A novel ex vivo is isolation and expansion procedure for chimeric antigen receptor engrafted human T cells[J].PLo S One,2014,9(4):e93745.

[25]Sadelain M,Rivière I,Riddell S.Therapeutic T cell engineering[J].Nature,2017,545(7655):423-431.

[26]Davila M L,Riviere I,Wang X,et al.Efficacy and toxicity management of 19-28,z CAR T cell therapy in B cell acute lymphoblastic leukemia[J].Science Translational Medicine,2014,6(224):224-225.

[27]Maude S L,Frey N,Shaw P A,et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].The New England Journal of Medicine,2014,371(16):1507-1517.

[28]Lee D W,Kochenderfer J N,Stetler-Stevenson M,et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:A phase 1 doseescalation trial[J].Lancet,2015,385(9967):517–528.

[29]Turtle C J,Hanafi L A,Berger C,et al.CD19 CAR-T cells of defined CD4+:CD8+composition in adult B cell ALL patients[J].Journal of Clinical Investigation,2016,126(6):2123–2138.

[30]Qasim W,Zhan H,Samarasinghe S,et al.Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells[J].Science Translational Medicine,2017,9(374):eaaj2013.

[31]Kochenderfer J N,Dudley M E,Kassim S H,et al.Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor[J].Journal of Clinical Oncology,2015,33(6):540–549.

[32]Sabatino M,Hu J,Sommariva M,et al.Generation of clinical-grade CD19-specific CAR-modified CD8+memory stem cells for the treatment of human B-cell malignancies[J].Blood,2016,128(4):519-528.

[33]Turtle C J,Hanafi L A,Berger C,et al.Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+and CD4+CD19-specific chimeric antigen receptor-modified T cells[J].Science Translational Medicine,2016,8(355):116.

[34]Kloss C C,Condomines M,Cartellieri M,et al.Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells[J].Nature Biotechnology,2013,31(1):71-75.

[35]Prosser M E,Brown C E,Shami A F,et al.Tumor PD-L1co-stimulates primary human CD8+cytotoxic T cells modified to express a PD1:CD28 chimeric receptor[J].Molecular Immunology,2012,51(3/4):263-272.

[36]Roybal K T,Rupp L J,Morsut L,et al.Precision tumor recognition by T cells with combinatorial antigen-sensing circuits[J].Cell,2016,164(4):770-779.

[37]Fedorov V D,Themeli M,Sadelain M.PD-1-and CTLA-4-based inhibitory chimeric antigen receptors(i CARs)ivert off-target immunotherapy responses[J].Science Translational Medicine,2013,5(215):172.

[38]Gazit R,Gruda R,Elboim M,et al.Lethal influenza infection in the absence of the natural killer cell receptor gene Ncrl[J].Nature Immunology,2006,7(5):517-523.

[39]Loris Z,Cristina P,Prisco M,et al.NK cells and cancer[J].Journal of Immunology,2007,27(45):5932-5943.

[40]Sutlu T,Alici E.Natural killer cell-based immunotherapy in cancer:Current insights and future prospects[J].Journal of Internal Medcine,2009,266(2):154-181.

[41]Vivier E,Ugolini S,Blaise D,et al.Targeting natural killer cells and natural killer T cells in cancer[J].Nature Reviews Immunology,2012,12(4):239-252.

[42]Vivier E,Ugolini S.Natural killer cells:From basic research to treatments[J].Frontiers in Immunology,2011,2:18.

[43]Ljunggren H G,Malmberg K J.Prospects for the use of NK cells in immunotherapy of human cancer[J].Nature Reviews Immunology,2007,7(5):329-339.

[44]Vivier E,Nunès J A,Vély F.Natural killer cell signaling path-ways[J].Science,2004,306(5701):1517-1519.

[45]Romagn E F,Vivier E.Natural killer cell-based therapies[J].F1000 Report Medcine,2011,3(1):9.

[46]Fehniger T A,Caligiuri M A.Interleukin 15:Biology and relevance to human disease[J].Blood,2001,97(1):14-32.

[47]Lucas M,Schaehterle W K,Aichele P,et al.Dendritic cells prime natural killer cells by trans-presenting interleukin 15[J].Immunity,2007,26(4):503-517.

[48]Cooper M A,Elliott J M,Keyel P A,et al.Cytokine induced memory like natural killer cells[J].Proceedings of the National Academy of Sciences of the United States of America,2009,106(6):1915-1919.

[49]Boissel L,Betancur M,Wels W S,et al.Transfection with m RNA for CDl9 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells[J].Leukemia Research,2009,33(9):1255-1259.

[50]Cheng M,Chen Y,Xiao W,et al.NK cell-based immunotherapy for malignant diseases[J].Cellular&Molecular Immunology,2013,10(3):230-252.

[51]Koepsell S A,Miller J S,Mc Kenna D H J.Natural killer cells:A review of manufacturing and clinical utility[J].Transfusion,2013,53(2):404-410.

[52]Higuchi M,Higashi N,Taki H,et al.Cytolytic mechanisms of activated macrophages.Tumor necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages[J].Journal of Immunology,1990,144(4):1425-1431.

[53]Kr?ncke K D,Fehsel K,Kolb-Bachofen V.Inducible nitric oxide synthase and its product nitric oxide,a small molecule with complex biological activities[J].Biological Chemistry Hoppe-Seyler,1995,376(6):327-343.

[54]Nathan C,Brukner L,Kaplan G,et al.Role of activated macrophages in antibody-dependent lysis of tumor cells[J].The Journal of Experimental Medicine,1980,152(1):183-197.

[55]王晓宁,范清宇,郝新保,等.胞壁酰二肽激活大鼠巨噬细胞抗肿瘤免疫效应的研究[J].细胞与分子免疫学杂志,1999,15(3):193-195.

[56]Balkwill F R,Mantovani A.Cancer-related inflammation:Common themes and therapeutic opportunities[J].Seminars in Cancer Biology,2012,22(1):33-40.

[57]Liu Y,Can X.The origin and function of tumorassociated macrophages[J].Cellular&Molecular Immunology,2015,12(1):1-4.

[58]Gordon S,Taylor P R.Monocyte and macrophage heterogeneity[J].Nature Reviews Immunology,2005,5(12):953-964.

[59]Weiskopf K,Weissman I L.Macrophages are critical effectors of antibody therapies for cancer[J].Mabs,2015,7(2):303-310.

[60]Kirby J A,Forsythe J L,Proud G,et al.Renal allograft rejection:Possible involvement of lymphokine-activated killer cells[J].Immunology,1989,67:62-67.

[61]Rosenberg S A,Spiess P,Lafreniere R.A new approach to the adoptive immunotherapy of cancer with tumorinfiltrating lymphocytes[J].Science,1986,233(4770):1318-1319.

[62]Yang M,Galina V S,Dmitriy W G,et al.Tumor associated regulatory dendritic cells[J].Seminars in Cancer Biology,2012,22(4):298-306.

[63]Xiao L,Joo K I,Lim M,et al.Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice[J].PLo S One,2012,7(11):e48866.

[64]Rong X,Wei F,Li A,et al.Effective activity of cytokine induced killer cells against hepatocellular carcinoma including tmor-initiating cells[J].Med Hypotheses,2015,84(3):159-161.

[65]Shi S B,Ma T H,Li C H,et al.Effact of maintenance therapy with dendritic cell:Cytokine-induced killer cells in patients with advanced non-small cell lung cancer[J].Tumori,2012,98(3):314-319.